NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2061210033

Registered date:04/09/2021

Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedAdvanced hepatocellular carcinoma
Date of first enrollment02/11/2021
Target sample size6
Countries of recruitmentUSA,China,Italy,Poland,South Korea,Spain,Switzerland,Taiwan,Japan
Study typeInterventional
Intervention(s)MK-1308A 25 mg/400 mg IV Q6W plus lenvatinib 12 mg (BW >=60 kg) or 8 mg (BW <60 kg) orally QD

Outcome(s)

Primary Outcome- Safety and tolerability. - Objective response rate (ORR)
Secondary Outcome- Duration of response (DOR) - Disease control rate (DCR) - Progression-free survival (PFS) - Time to progression (TTP) - Overall survival (OS)

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria- Has an hepatocellular carcinoma (HCC) diagnosis confirmed by radiology, histology, or cytology (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) - Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach - Has a Child-Pugh class A liver score within 7 days prior to first dose of study intervention - Has a predicted life expectancy of >3 months - Has at least 1 measurable HCC lesion based on RECIST 1.1, confirmed by BICR - Has an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 to 1 within 7 days prior to first dose of study intervention - Participants with controlled hepatitis B will be eligible as long as they meet the following criteria: antiviral therapy for Hepatitis B virus (HBV) must be given for at least 4 weeks and HBV viral load must be less than 500 IU/mL prior to first dose of study drug - Has adequately controlled blood pressure with or without antihypertensive medications - Has adequate organ function
Exclude criteria- Has had esophageal or gastric variceal bleeding within the last 6 months. - Has bleeding or thrombotic disorders or use of factor X inhibitors or anticoagulants requiring therapeutic international normalized ratio (INR) monitoring, e.g., warfarin or similar agents - Has clinically apparent ascites on physical examination - Has inferior vena cava or cardiac involvement of HCC based on imaging - Has had clinically diagnosed hepatic encephalopathy in the last 6 months unresponsive to therapy - Has medical contraindications that preclude all forms of contrast-enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) - Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib - Has a preexisting Grade >=3 gastrointestinal or non-gastrointestinal fistula - Has clinically active hemoptysis (bright red blood of a least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug - Has clinically significant cardiovascular impairment within 12 months of the first dose of study intervention, including New York Heart Association (NYHA) Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability - Has had major surgery to the liver within 4 weeks prior to the first dose of study intervention - Has had a minor surgery (i.e., simple excision) within 7 days prior to the first dose of study intervention (Cycle 1 Day 1) - Has serious nonhealing wound, ulcer, or bone fracture - Has received any systemic chemotherapy, including anti- vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agents for treatment of HCC - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor - Has received locoregional therapy to liver within 4 weeks prior to the first dose of study intervention - Has received prior radiotherapy to a non-liver region within 2 weeks of start of study intervention - Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years - Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis as assessed by local site investigator - Has severe hypersensitivity (>=Grade 3) to study intervention and/or any of their excipients - Has an active autoimmune disease that has required systemic treatment in past 2 years - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease - Has an active infection requiring systemic therapy, with the exception of HBV or Hepatitis C virus (HCV) - Has a known history of human immunodeficiency virus (HIV) infection - Has dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and HCV infection (anti-HCV antibody [Ab] positive and detectable HCV RNA) at study entry - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator - Has a known psychiatric or substance abuse disorder that would interfere with the participants ability to cooperate with the requirements of the study - Has had an allogenic tissue/solid organ transplant

Related Information

Contact

Public contact
Name MSDJRCT inquiry mailbox
Address KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan Tokyo Japan 102-8667
Telephone +81-3-6272-1957
E-mail msdjrct@merck.com
Affiliation MSD K.K.
Scientific contact
Name Toshifumi Hoki
Address KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan Tokyo Japan 102-8667
Telephone +81-3-6272-1957
E-mail msdjrct@merck.com
Affiliation MSD K.K.